Mochida Pharmaceutical Co., Ltd.

4534

JP3922800002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-01 am EDT			5-day change	1st Jan Change
3,205 ^JPY	+0.47%		+1.26%	-1.99%

Apr. 25	Hidehiro Imatsu named president of Goldman Sachs Japan	RE
Mar. 21	Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	CI

Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

May 15, 2023 at 01:00 am EDT

Mochida Pharmaceutical Co., Ltd. provided second quarter-end and year-end dividend guidance for the fiscal year ending March 31, 2024. For the second quarter-end, the company expects to pay dividend of JPY 40.00 per share against JPY 40.00 per share paid a year ago.

For the year-end, the company expects to pay dividend of JPY 40.00 per share against JPY 40.00 per share a year ago.

Latest news about Mochida Pharmaceutical Co., Ltd.

Hidehiro Imatsu named president of Goldman Sachs Japan	Apr. 25	RE
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	Mar. 21	CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 1,080,000 shares, representing 2.97% for ¥3,485.1 million.	Mar. 18	CI
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024	Feb. 05	CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Feb. 05	CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	Jan. 04	CI
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024	Nov. 02	CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Nov. 02	CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	23-10-02	CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-08-04	CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-08-04	CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	23-07-03	CI
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1%	23-05-16	MT
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-05-15	CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-05-15	CI
Mochida Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 30, 2023	23-05-15	CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,080,000 shares, representing 2.96% for ¥3,500 million.	23-05-15	CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-05-14	CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.	23-03-23	CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 1, 2022, has closed with 1,036,200 shares, representing 2.78% for ¥3,499.72 million.	23-03-21	CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.	23-01-04	CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 1, 2022.	22-10-03	CI
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.	22-08-01	CI
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	22-07-31	CI

Chart Mochida Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mochida Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3,205 JPY

Average target price

3,200 JPY

Spread / Average Target

-0.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOCHIDA PHARMACEUTICAL CO., LTD.	-1.99%	719M
ELI LILLY AND COMPANY	+33.25%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.55%	348B
MERCK & CO., INC.	+18.16%	327B
ABBVIE INC.	+4.36%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	147B

Other Pharmaceuticals